Dr Erin Hurst
Dr Erin Hurst is a consultant haematologist specialising in blood cancers and bone marrow transplantation.
Dr Hurst graduated from Newcastle University in 2005 and completed her junior doctor training in the North East, becoming a consultant at the Freeman Hospital in 2015.
Working as part of the haemato-oncology team, Dr Hurst manages blood cancers and myelodysplastic syndromes. She also works as part of the bone marrow transplant team managing patients from referral and initial assessment, through transplant into long term follow-up.
Dr Tobias Menne
Dr Tobias Menne is a haematologist specialising in acute lymphoblastic leukaemia, lymphoma and CAR-T cell therapies.
Since September 2021 Dr Menne is the clinical director for research at Newcastle Hospitals. He is the regional sub-speciality research lead for haemato-oncology, clinical haem/onc research lead and lead for immune effector cell therapy. He is a member of the national Lymphoma Clinical Study Group and the national Low Grade and High Grade Lymphoma Working Groups and the Adult Acute Lymphoblastic Leukaemia Working Group.
Research
He has a special interest in lymphoma and acute lymphoblastic leukaemia. He is actively involved in clinical research. Dr Menne is Chief Investigator on the TIDaL (testing upfront ibrutinib and rituximab therapy in PTLD) and SELUDex trials (testing the MEK inhibitor Selumetinib in R/R ALL), as well as a member of the Trial Management Group for UKALL14 , PETReA trials and the upcoming UKALL15, and POLARICE trials. He is PI on several CAR-T cell studies in lymphoma and myeloma.
Dr Wendy Osborne
Dr Wendy Osborne is a consultant haematologist at the Freeman Hospital. She graduated with first class honours from Newcastle University in 1998 and completed her general medical training at Queens Medical Centre, Nottingham. She worked in haematology departments in Glasgow before returning to Newcastle to undertake higher specialist training.
Dr Osborne is chair of the British Society of Haematology Lymphoma Special Interest Group and a member of the NCRI Clinical Studies Group, High Grade lymphoma sub-group and Hodgkin lymphoma subgroup. She is on the medical advisory panel for Lymphoma Action and is a principal investigator and co-investigator for numerous clinical trials. Dr Osborne is an honorary clinical senior Lecturer at Newcastle University and teaching lead for the haematology undergraduate programme.
Dr Helen Marr
Dr Helen Marr is a consultant haematologist specialising in chronic lymphocytic leukaemia, lymphoma, and autologous bone marrow transplant.
Dr Marr qualified from University of Nottingham in 2002 and completed her general medical training in Newcastle, before working in Christchurch, New Zealand as a haematology registrar for 18 months. She completed her specialty haematology training in Newcastle and Northern Deanery and subsequently took time out to complete a PhD in chronic lymphocytic leukaemia from 2012-2015.
After finishing her specialty training, Dr Marr worked in the Freeman Hospital as a clinical fellow in research, helping with recruitment and management of patients on haematology clinical trials, before taking up her consultant post in 2017.
She is the chair of the regional haematology MDT and sits on the UK CLL Forum committee.
Dr Thomas Creasey
Dr Tom Creasey is a consultant haematologist at the Northern Centre for Cancer Care. He specialises in the treatment of patients with blood cancers, particularly myeloma and lymphoma. He qualified from Newcastle University medical school in 2008 and completed his post-graduate training in Nottingham and the North East, before he was appointed as a consultant at the Freeman Hospital in 2021.
He completed a PhD between 2017-2021 where he researched the genetic landscape of acute lymphoblastic leukaemia in older adults and has a specific interest in the role of genetic risk stratification in blood cancers.
